The administration of large doses of selenium (Se) to rats leads to reduced serum levels of somatotropin (growth hormone) and insulin-like growth factor-1 (IGF-1), followed by growth retardation. Similar experiments in humans have been contradictory. The effects of wheat Se and selenomethionine supplementation were investigated in healthy, Norwegian women. In study 1, the participants (n = 18) were given Se-rich bread with 100, 200 and 300 μ § Se daily for 6 weeks. Initial serum Se concentration were 1.5 ± 0.2 μιηοΐ/ΐ (mean ± SD). Serum Se increased in a dose-dependent manner in the three groups (p < 0.001). There was no effect on somatotropin and IGF-1 at any of the Se doses given. In study 2 (n = 24), the effects of 400 μg selenomethionine daily for 15 weeks were studied in a placebo controlled study. In the treatment group, serum Se concentrations increased by more than 100%. There was, however, no effect on serum somatotropin and IGF*1 concentrations, nor was there any effect on IGF-binding proteins 1 and 3. Our results indicate that at normal or slightly increased intakes, Se has no effect on the serum concentrations of these two hormones in healthy individuals.
Introduction
mark and Norway to warn against Se supplements in 1989 Growth retardation is a typical finding in animals exposed to toxic doses of selenium (Se) (1, 2, 3) . It is also Due to import of Se-rich wheat from USA and Canada, a regular finding in stocks with alkali disease, a Se tox-wheat is the main dietary source of Se in Norway. At icity syndrome (for review, 1. c. (4, 5) ). Growth retarda-least 50% of the Se in wheat is in the form of selenotion seems to appear irrespective of Se being adminis-methionine (11) , which is also used in a number of comtered in an inorganic or organic form (6, 7) . Recently, mercial Se supplements. Numerous studies have demonThorlacius-Ussing and coworkers reported that somato-strated that selenomethionine, as well as wheat Se, has tropin treatment of selenite exposed rats restored their high bioavailability (12) (13) (14) (15) (16) . The purpose of the two normal growth rate although serum insulin like growth studies presented here was to study the effects of factor 1 (IGF-1) concentrations were still subnormal (8, increasing daily amounts of wheat Se and selenomethio-9). Moreover, when selenite exposure was discontinued, nine on the serum concentrations of somatotropin, IGFserum somatotropin concentrations returned to normal i, IGF-binding protein 1 and IGF-binding protein 3 in while IGF-1 concentrations remained low.
healthy, young, Norwegian women.
In a Danish Se supplementation trial 256 μg yeast Se was given daily to rheumatics for six months, leading to a significant reduction in the serum concentration of Methods IGF-1 (10) . The results of the animal studies and the We report here the results from two studies Study , was conducted of Se have been published previously (15) . Unpublished results from that study indicated that wheat Se had no effects on serum growth hormone and 1GF-1 concentrations. However, IGF-1 circuFates bound to specific binding proteins, and it was important to see wether Se treatment affected serum levels of these binding proteins. Moreover, one could not exclude the possibility that somewhat higher Se doses might have an effect. A new study was, therefore, carried out in 1992 (study 2), with selenomethionine given at the highest level that is, generally, deemed safe, and serum levels of IGF binding proteins were measured.
Subjects
Study 1: Eighteen female students at the age of 20-26 volunteered to participate in the study, and written consent was given by each subject, in complicance with the ethical standards then in use.
Study 2: Twenty-four female students at the age of 20-40 participated. All participants gave informed consent and the study protocol was approved by the Regional Ethics Committee of Medical Research, Region II, Norway.
None of the participants in the two studies had taken Se-containing supplements the last three months prior to the studies. They were all in good health, and they were non-smokers. None of the subjects were pregnant or lactating, and they used no medication. Four participants in study 1 and seven in study 2 used oral contraceptives. In study 1; all subjects were encouraged to maintain their usual daily routines and dietary habits during the study. In study 2, 16 out of the 24 participants were encouraged to eat as much fish as possible, at least three dinner servings per week, during the study. As the fish eating had no influence on any of the results reported here, 'eaters and non-eaters' of fish were pooled in the subsequent analyses. The initial values of serum Se, body mass index and age are given in table 1.
dietary Se intake of 80 μg/10 MJ (17) . With an average energy intake of 9.2 MJ/day, the daily Se intake was estimated to be approximately 75 μg. Accordingly, the total Se intake in the intervention period in study 1, corrected for the substituted normal bread slices, was estimated to be 160 μ& 260 μg and 360 μg Se daily for the three groups, respectively. In study 2 the total average Se intake would be approximately 475 μg/d in the study group and 75 μg/d in the control group.
Analytical methods
The concentrations of Se in serum and blood were determined by atomic absorption spectrometry using a hydride generator system (Varian AA-1475, VGA-76) after digestion in a mixture of nitric and perchloric acid (18, 19) . The results are expressed in μπιοΐ/ΐ.
Somatotropin was measured using an immunoradiometric assay developed at the Hormone laboratory. The intra-and inter-assay precisions are 6% and 10%, respectively. The normal range for women is 0.6-7.2 mIU/1.
IGF-1 was measured after extraction (CM 8) using a radioimmunoassay from Nichols Institute Diagnostics (USA). The intra-and inter-assay precisions are 7% and 12%, respectively. The normal range for women is 15-35 nmol/1.
IGF binding protein-1 was measured using an immunofluororfietric assay developed at the Hormone laboratory. The intra-and interassay precisions are 8% and 16%, respectively. The normal range for women is 0.02-0.47 nmol/1.
IGF binding protein-3 was measured using a radioimmunoassay from Diagnostic System Laboratories (USA). The intra-and interassay precisions are 5% and 8%, respectively. The reference range for women is 63-280 nmol/1.
Experimental design
Study I: The subjects were randomized into three groups. For six weeks the participants were given Se-rich bread, group 1 (n = 6) receiving 100 μg, group 2 (n = 6) 200 μ» and group 3 (n = 6) 300 μg Se per day. The slices replaced bread otherwise consumed during the day.
Study 2:
The subjects were randomized into 2 groups. Group 1 (n = 16) received 400 μg Se in the form of selenomethionine containing tablets daily, while group 2 (n = 8) received placebo tablets for 15 weeks.
Samples
Blood samples were obtained by venipuncture in the morning after a 12-hour fast, in study 1 at weeks 0, 3 and 6, and in study 2 at weeks 0 and 15. 
Diet and supplements

Study 2:
Selenomethionine and placebo tablets were kindly provided by Pharma Nord A/S, Denmark. The tablets were identical in taste and appearance. Each active tablet contained 100 μg selenomethionine, and both groups were given 4 tablets per day.
Previous analysis of Se intake in similar groups of Norwegian women, using the duplicate portion technique, indicated a mean
Statistics
The large variances observed for some of the quantities measured in this study are normal and may be an indicator for the use of non-parametric statistics. In the present study, non-parametric methods were in a few cases more powerful than the parametric, but in no case did they give significant results. 
Results
Serum and blood Se concentrations
The initial serum concentrations of Se were similar in the different study groups in both studies (tab. 1). Serum Se increased, as previously reported, in a dose-related manner in study 1, i. e. by 0.25, 0.47 and 0.67 μπιοΐ/l in the three groups, respectively (p < 0.001 (15) . In the selenomethionine-group (study 2), Se concentrations increased by 1.99 and 3.29 μιηοΐ/ΐ (ρ < 0.001) in serum and blood, respectively. Serum and blood concentrations of Se were strongly correlated throughout the study. There was no change in serum or blood Se concentrations in the placebo group.
Somatotropin
Study 1: As shown in table 2, initial somatotropin concentrations varied between the groups, groups 1 and 2 being significantly different, ρ < 0.05, from group 3.
Mean concentrations for all groups increased by week three (NS) and increased further in groups 1 and 2 by week six (NS), while in group 3 a decline was found after 6 weeks, resulting in almost identical growth hormone concentrations by the end of the supplementation period.
Study 2:
There was a non-significant decline in somatotropin concentrations in the placebo group, but the two groups had comparable concentrations during the whole study (tab. 2).
Insulin-like growth factor-1 and binding proteins the concentration of both IGF-binding proteins decreased (NS) in the placebo group (tab. 2).
Correlations
There were no correlations between the serum levels of Se and somatotropin in any of the study groups during the two studies. The concentrations of serum Se correlated weakly and positively (NS) with IGF-1 at the start of the study in study 1, while the correlation was negative (NS) in study 2 (r = -0.40, p = 0.054). Blood Se and serum IGF-1 concentrations showed a significant, negative correlation at the start of study 2: r = -0.54, p = 0.007, the corresponding correlation between serum Se and IGF-1 being r = -0.40, p = 0.054. There was, however, no correlation between these quantities at the end of the study ( fig. 1) . Moreover, there was no correlation between changes in the concentrations of serum Se and IGF-1 in the two studies.
Neither initial IGF binding protein-1 and IGF binding protein-3 concentrations nor changes in these analyses correlated with 'serum Se concentrations at any point during study 2.
Discussion
Animal studies have shown that strongly increased blood Se values are associated with decreased serum levels of IGF-1, suggesting that Se may suppress the secretion of growth hormone and/or IGF-1 (8) (9) (10) The metabolism of Se seems to be perturbed in rheumatoid arthritis (22) . In this patient group, Se incorporation into the Se-dependent enzyme glutathione peroxidase 1 ) is suppressed, and the polymorphonuclear leukocytes, that ordinarily are among the Se-richest cells iri the body, do not increase their Se content in response to Se supplementation (22) . In a rat model, high-dose selenite supplementation resulted in a high accumulation of Se in the anterior pituitary, especially in the secretory granGlutathione peroxidase (EC 1.11.1.9) Eur J Clin Chem Clin Biochem 1995; 33 (No 7) ules of the somatotrophs (23) . The Se accumulation resulted in impaired pituitary and hepatic function. It may be speculated that a redistribution of Se may explain the IGF-1 lowering effect of Se supplementation observed in rheumatoid arthritis (10) . Models for normal selenomethionine kinetics are developed in 1. c. (24) . It may also be speculated that the circulating proteolytic activity observed during several illness conditions (21) , and responsible for IGF binding protein-3 degradation, is somehow effected by Se.
In summary, our results show that moderate Se supplementation has no significant effects on serum levels of growth hormone, IGF-1, IGF binding protein-1 and IGF binding protein-3. Our results are thus in accordance with the lack of epidemiological evidence for growth retardation in moderately high-selenium areas of the world.
